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Treatment resistance (TR) in patients with first-episode
psychosis (FEP) is a major cause of disability and functional impairment, yet mechanisms underlying this severe
disorder are poorly understood. As one view is that TR has
neurodevelopmental roots, we investigated whether its emergence relates to disruptions in synchronized cortical maturation quantified using gyrification-based connectomes.
Seventy patients with FEP evaluated at their first presentation to psychiatric services were followed up using clinical
records for 4 years; of these, 17 (24.3%) met the definition of TR and 53 (75.7%) remained non-TR at 4 years.
Structural MRI images were obtained within 5 weeks from
first exposure to antipsychotics. Local gyrification indices
were computed for 148 contiguous cortical regions using
FreeSurfer; each subject’s contribution to group-based
structural covariance was quantified using a jack-knife
procedure, providing a single deviation matrix for each
subject. The latter was used to derive topological properties that were compared between TR and non-TR patients
using a Functional Data Analysis approach. Compared to
the non-TR patients, TR patients showed a significant reduction in small-worldness (Hedges’s g = 2.09, P < .001)
and a reduced clustering coefficient (Hedges’s g = 1.07, P
< .001) with increased length (Hedges’s g = −2.17, P <
.001), indicating a disruption in the organizing principles of

cortical folding. The positive symptom burden was higher
in patients with more pronounced small-worldness (r = .41,
P = .001) across the entire sample. The trajectory of synchronized cortical development inferred from baseline
MRI-based structural covariance highlights the possibility
of identifying patients at high-risk of TR prospectively,
based on individualized gyrification-based connectomes.
Key words: first-episode psychosis/treatment-resistant/cl
ozapine/longitudinal/gyrification/MRI/schizophrenia
Introduction
Approximately 30% of patients with a diagnosis of schizophrenia spectrum disorders will experience insufficient
treatment response to available treatments, a phenomenon known as treatment resistance (TR).1,2 In line with
existing evidence,3 we have previously shown that around
70% of patients with first-episode psychosis, who later
develop TR, already exhibit a lack of response to nonclozapine antipsychotic treatments from their first contact with mental health services, while a remaining 30%
become non-responsive at later stages.4,5 This, in combination with evidence that a history of obstetric complications6,7 and a younger age of illness onset are associated
with a greater risk of developing TR,4,8,9 suggests that
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neurodevelopmental disruption may play a crucial role in
the pathophysiology of TR.
Alterations in cortical folding (gyrification), which is
an excellent marker of the integrity of axonal connectivity during the prenatal period,10 as demonstrated in the
classic lesional studies of Goldman-Rakic and Rakic,11
have been reported in patients with psychosis,12,13 including in association with lack of response to antipsychotic treatment.14 While age-related reductions in the
degree of gyrification occur after birth, when compared
to the effects on cortical thickness and volume, regional
alterations in gyrification index with age are minimal.15
Regional or mass univariate whole brain analysis of morphological measures such as gyrification, reveals brain
regions that are most susceptible to focal disease-related
change.16–19 Nevertheless, in the presence of significant
pathophysiological heterogeneity, as that suspected in
TR, the presence of these changes may be subtle and
differ across patients, leading towards the identification
of null results and to inconsistency on repeated casecontrol sampling.20 Focussing on regional alterations also
fails to quantify the relationship between concomitant
changes across different brain areas, which is crucial to
uncovering the presence of defects in synchronized maturation. Graph-based measures of structural covariance
provide a more powerful mode of capturing defects in synchronized maturation.21 When applied to the gyrification
index, this approach likely captures the state of axonal
connectivity occurring during prenatal development,22
making it one of the most promising methods for tracing
the basis of TR back to factors that predate the onset of
symptoms in psychosis. Additionally, deriving network
metrics for the individual patient, which is at the core of
the perturbation-based network analyses that compute
an individual’s distance from a group norm,23 further allows for quantification of the heterogeneity inherent to
many clinical subgroups.
Therefore, this study investigated if the emergence of
TR in the 4 years following the first episode of psychosis
is already associated with alterations in individual structural covariance of cortical gyrification at illness onset.
While there are multiple metrics available to study cortical structure,24,25 the utility of structural covariance
approaches in the study of psychoses, including schizophrenia, has been established only for thickness26 and
gyrification,22 and among these, gyrification appears to be
less malleable to environmental influences.22 In this context, and in continuity with our prior work,14,27,28 we chose
the gyrification index as the metric of interest for this
study. As treatment-resistant psychosis appears to have a
unique neurobiological basis, different from that of partially treatment-responsive psychosis, we used a categorical definition of TR. We hypothesized that patients with
first-episode psychosis who later developed TR would
already show evidence of alterations in synchronized
1730

cortical maturation at the time of their first contact with
mental health services.
Methods
Sample Ascertainment
Participants were recruited as part of the National
Institute of Health Research (NIHR) Biomedical
Research Centre (BRC) Genetics and Psychosis (GAP)
study conducted in South London, United Kingdom.29
In line with previous research,3,30 we included all individuals aged 16–65 years with a first episode of schizophrenia spectrum disorders [codes F20–F29], affective
psychoses [F30–F33] or other psychoses as defined
in the International Classification of Diseases, 10th
Revision (ICD-10) manual.31 These diagnoses were further validated by administration of the Schedules for
Clinical Assessment in Neuropsychiatry (SCAN).32 The
study exclusion criteria were evidence of (1) psychotic
symptoms precipitated by an organic cause; (2) transient psychotic symptoms resulting from acute intoxication as defined in ICD-10; (3) head injury causing
clinically significant loss of consciousness; and (4) intellectual disability (IQ < 70).
Ethics
The GAP study was granted ethical approval by the
South London and Maudsley and Institute of Psychiatry
Local Research Ethics Committee (reference number:
05/Q0706/158). All cases gave informed written consent
after reading a detailed information sheet.
Data at Baseline
Sociodemographic
Characteristics. Sociodemograp
hic details were collated using the Medical Research
Council (MRC) Sociodemographic Schedule modified version.33 Age at first contact with services was
defined as age at which a patient was first in contact
with mental health services due to their psychotic
symptoms.34 Ethnicity was self-ascribed using the 16
categories of the UK Census in 2001 (www.statistics.
gov.uk/census 2001).
Clinical Assessments. Duration of untreated psychosis
(DUP) was defined (in weeks) as the difference between
the date of onset of psychotic symptoms and the date of
treatment with antipsychotic medications.35,36 The Global
Assessment of Functioning (GAF) scale was used to
measure both overall symptoms severity and functional
disability at study entry.37 The GAF was completed from
face-to-face interviews with good inter-rater reliability
(κ = 0.90). The degree of psychopathology over the preceding week was evaluated with the 30-item Positive and
Negative Syndrome Scale (PANSS),38,39 in face-to-face
interviews. Each PANSS item was rated on a 7-point scale
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(1 = absent, 7 = extreme), across all 3 subscales: positive
symptoms (7 items), negative symptoms (7 items), and
general psychopathology (16 items).
MR Image Acquisition and Processing
To ensure minimal exposure to antipsychotic medications
in patients, MRI scans were obtained within a 3-month
period following the first contact with psychiatric services. A 3 Tesla GE (General Electric, Milwaukee)
Signa HDx scanner at the Centre for Neuroimaging
Sciences (CNS), Institute of Psychiatry, Psychology and
Neuroscience (London, UK) was used to acquire 3-dimensional MPRAGE volumetric scans (matrix size of
256 × 256 × 166 voxels, with in-plane voxel size of 1.02 ×
1.02 mm and a slice thickness of 1.2 mm (echo time/repetition time/inversion time = 2.848/6.988/650 ms, excitation flip angle 20°, one data average). Full brain and skull
coverage was required for the MRI datasets and detailed
quality control was carried out on all MR images according to previously published criteria.14,27,40 A summary
of the quality control criteria used is presented in the supplementary material.
Cortical Gyrification Analysis. We computed local
gyrification indexes (LGIs) for various anatomically defined sulcal and gyral regions of the cortical mantle
using Freesurfer (FreeSurfer, version 4.5.0; http://surfer.
nmr.mgh.harvard.edu/), based on the method by Schaer
et al.41 The steps for constructing an individual-specific
LGI network are presented in figure 1; more details on
surface extraction are provided in the supplementary material. LGIs were computed for 148 parcellated brain regions (74 in each hemisphere; no subcortical structures
included) according to the atlas of Destrieux et al42 and
in line with our prior work on structural covariance.14,27
All pre-processing steps followed the standard description given by Fischl et al.43 This included skull-stripping,
intensity correction, determination of the gray-white
matter boundary followed by tessellation to generate multiple vertices across the whole brain and the expansion
of this boundary to re-create the pial surface, followed
by spherical morphing and registration using sulcogyral
landmarks. Schaer’s automated vertex-wise method computes Zilles’ gyrification index,44 a ratio of the inner
folded contour to the outer perimeter of the cortex, using
a 25 mm hull surface around each vertex of the reconstructed pial surface.41 Averaging the gyrification values
assigned to the vertices within each anatomical boundary
of Destrieux parcellations provided the regional LGI
measure for each of the 148 parcellated brain regions.
An LGI value closer to 1 suggests that the region has an
approximately flat pial surface with almost no “buried
cortex” in sulcal ridges.
Constructing Gyrification-Based Individual Covariance
Networks. We first generated a 148 × 148 correlation
matrix based on LGI values, separately for the 2 study

groups. We estimated the contribution of each individual to their group matrix using a jack-knife bias
estimation procedure, in line with our prior study.45
Bias values for each cell in the matrix of an individual
subject quantified the contribution of that subject to
the structural covariance of their group. Higher values
signify greater relationship between the 2 given nodes
in that subject, relative to the group norm. As a result,
everyone’s matrix is a representation of the absolute
contribution of that individual to their group’s overall
covariance structure. This approach is mathematically
similar to individual-specific gene expression networks used in bioinformatics23,46 and cancer studies.47
The bias values that constitute the edges in a group
perturbation-based deviance matrix show a smooth,
symmetric distribution around the absolute group
correlation value, enabling parametric inferences, as
shown by Liu et al.46 We then used the Graph Analysis
Toolbox,48 to generate binary undirected graphs with
a range of network thresholds based on connection
density (ie, 0.05–0.25, with interval steps of 0.01). The
interval steps were chosen to generate sufficient data
points (20) for the functional data analysis (FDA)
described below. This proportional thresholding and
binarization based on edge density ensured that differences in absolute bias values between the 2 groups
(that relate to the degree of freedom in jack-knife estimates) did not influence the estimates of topological
parameters. The proportional thresholding range was
chosen to enable between-group comparisons without
inducing disconnection (percolation threshold) or
losing small-worldness (randomness threshold) in
any of the groups.49 Topological properties become
unstable when sparsity levels are too high as some
nodes are fully disconnected, while weak pairwise relationships that are likely to introduce randomness are
included at lower sparsity values.49 See figure 1 for further details.
Tracing Patients at Follow-up
Approximately 4 years (mean = 3.8, SD = 1.4;
range = 1–9, 283 person years) after the first contact
with psychiatric services, we sought to trace all patients who had given consent for their clinical records
to be accessed for research purposes. Follow-up data
on illness course were extracted retrospectively from
electronic clinical records, the primary clinical record
keeping system within the Trust,50 using the WHO Life
Chart Schedule (LCS) extended version,51,52 with has
good reliability.53 All deaths and migrations up to, and
including those that occurred during, the final year
of follow-up were identified by a case-tracing procedure with the Office for National Statistics (ONS) for
England and Wales and the General Register Office
(GRO) for Scotland.
1731

O. Ajnakina et al

Fig. 1. Depicts 3 steps (referred to as A, B, and C) followed to construct an individual-specific LGI network in the present study. (A) For
a single group of (N-1) subjects (treatment resistance [TR] or non-TR), a specific group-based network is constructed by the correlations
between LGI values based on regional LGI measures from 148 parcellations in this group, with the exclusion of a single subject i. This
group network (based on N-1 matrix) has the “normative” covariance structure of that group’s gyrification pattern. (B) A new subject
i belonging to that patient group is added to the group, and the perturbed network with this additional individual is constructed in
the same way as the (N-1) matrix. The difference between the (N) and the (N-1) network is due to the individual i (or j or k…). (C) An
individual contribution-based network is constructed using the difference of the corresponding edge between the (N) and (N-1) matrix.
For illustrative purposes, only one group (TR) and only 3 nodes are shown. LGI-based networks in this study were made of 148 nodes,
each node representing a single region of the parcellation scheme.

Definitions of TR. Patients were defined as having TR if
they had been treated with clozapine and/or they showed
little or no symptomatic improvement to 2 consecutive
treatments with antipsychotic medications of adequate
dose and duration (at least 6 weeks) during the follow-up
period.4,54 The presence of no symptomatic improvement
following antipsychotic treatment was established if (1)
having been treated with an antipsychotic medication
of adequate dose and for an adequate duration, patients
did not show improvement in their clinical presentation
as recorded by treating clinicians, and/or (2) the documented reason for switching antipsychotic medication
was a lack of therapeutic response, and not intolerance
1732

to antipsychotic medications or self-discontinuation of
medications.4 An adequate daily dose of antipsychotic
medication was defined as a daily dose of at least 400mg
of chlorpromazine equivalents.55
Data Analysis
Confirmatory Factor Analysis. As the Wallwork/
Fortgang’s model56 offered the most robust model for
exploring symptom profiles, we conducted a confirmatory factor analysis (CFA) to identify and evaluate
the statistical fit57 of these symptom dimensions in our
sample. The Goodness-of-Fit Index (GFI) statistics
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included the comparative fit index (CFI; values greater
than 0.90 indicate good model fit), the root mean
square error of approximation (RMSEA; values less
than 0.06 indicate good model fit), and the standardized root mean square residual (SRMR; values less than
0.08 indicate good model fit).57 To improve the model
fit, we further included correlated measurement errors
into the model, based on significantly correlated residuals as indicated by modification indices.58 With this
approach, 5 core symptom dimensions (positive, negative, excited, disorganized/concrete, and depressed59)
were estimated for each patient.
Topological Analyses. Global network properties
were quantified using small-worldness (σ), characteristic path length (λ) and clustering coefficient (ϒ).
While there are multiple measures of network properties available, we chose a minimal set with an index
reflecting the “segregation” that may result from modular (communal) development of gyrification within a
cluster of regions that increases clustering (ϒ); and an
index of “integration” indicating a coordinated maturational process in gyrification across the entire brain,
that reduces path length (λ). The presence of high segregation in the context of optimum integration gives
rise to small-worldness, measured using the smallworld index (σ). Network measures were normalized
to equivalent values derived from 20 random (“null”)
networks with the same degree of distribution, in line
with previous studies.45,60 To perform statistical group
comparisons across the range of chosen densities, we
constructed curves showing the change in measures of
interest as a function of the density. Functional data
analysis (FDA) was performed with network measures
treated as a function of y = f(x), allowing summation
across densities and obviating the need for multiple
testing (inline with61) using the GAT software.48 Oneway ANOVA was used to compare the density function
obtained using FDA between the 2 groups, followed by
an estimation of the unbiased effect sizes using Hedges
g.
Results
Core Analytic Cohort
The sample comprised 84 patients at first contact with
services for an episode of psychosis, with an average age
of 29.6 (SD = 9.8) years. After an average of 4 years, 10
(11.9%) were lost to follow-up and 74 (88.1%) were successfully followed up (mean years = 3.7, SD = 1.4). At
onset, patients lost to follow-up were more likely to live
with others (x2(1) = 3.88, P =.049) and to have a higher
GAF symptom score (t(53) = 3.08, P =.003). There were no
other significant differences between those patients who
were followed up and those who were lost to follow-up
(supplementary table 1). Among patients who were

followed up, 4 (5.4%) did not have sufficient information
to establish whether they had developed TR. Therefore,
the core analytic sample included in subsequent analyses
comprised 70 patients with an average age of 28.2 years
(SD = 7.3). Of these, 17 (24.3%) met criteria for TR at
the end of the follow-up period, while 53 (74.7%) were
defined as non-TR.
Comparisons Between TR and Non-TR Groups
Baseline sociodemographic and clinical characteristics of
the TR and non-TR groups are presented in table 1. There
were no significant differences between the 2 groups in
baseline sociodemographic and clinical characteristics.
There were also no differences in age at first contact with
services between the TR (meanyears = 25.8, SD = 5.4) and
non-TR groups (meanyear = 28.8, SD = 7.8; t(68) = 1.47,
P =.146).
Confirmatory Factor Analysis
The CFA of our core analytic sample produced an excellent fit of the model: CFI = 0.959, RMSEA = 0.052 (90%
CI 0.037–0.067), and SRMR = 0.071. There were no significant differences between TR and non-TR groups in
these symptom dimensions. Scores for PANSS items the
2 are presented in supplementary table 2.
Gyrification-Based Connectome and TR
Results from the graph analyses are presented in table 2.
Compared to patients in the non-TR group, patients
in the TR group had a significant reduction in smallworldness (Hedges’s g = 2.09, P < .001) and reduced
clustering coefficient (Hedges’s g = 1.07, P < .001) with
increased path length (Hedges’s g = −2.17, P < .001). As
shown in figure 2, having adjusted the analyses for age,
gender and TR status, the positive symptom dimension
was positively correlated with higher small-worldness
(r = .41, P =.001) across the entire sample. This relationship was in the same direction, although not statistically
significant, when the correlation was performed in the TR
and non-TR groups separately (r = .26 to 0.35, P = .07–
.2; supplementary figure 2). There were no similar correlations with the other symptom dimensions (table 3).
We also undertook a direct comparison of the LGI
values of the 148 regions between the TR and non-TR
groups, with False Discovery Rate (FDR) corrected at
P < .05 as threshold for significance. This comparison
did not identify any between-group difference, indicating
that disruptions in the covariance pattern of gyrification
(based on (σ, ϒ, and λ) are more pronounced than any
subtle difference in absolute regional cortical folding. The
uncorrected comparisons of LGI values for the 148 regions are presented in supplementary table 3.
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Table 1. Baseline Sample Characteristics for the Non-TR and TR Groups
Baseline Characteristic

Ageyears
Follow-up lengthyears
Time from starting AP to MRIdays
DUP weeks
Gender
Female
Male
Ethnicity
White ethnic groups
Black ethnic groups
Other
Living arrangements
Alone
Not alone
Relationship status
Single/separated
Stable relationship
Clinical presentation
GAF symptoms
GAF disability
Positive symptom dimension
Negative symptom dimension
Disorganisation dimension
Excited symptom dimension
Depressed symptom dimension
Baseline diagnosis
Schizophrenia spectrum disorders
Affective psychoses
Other

Non-TR, N = 53 (75.7%)

TR, N = 17 (24.3%)

Mean (SD)/N(%)

Mean (SD)/N(%)

t/U/x2

df

P

25.8 (5.4)
4.6 (0.78)
Range = 3–6
48.3 (37.0)
50.7 (114.2)

1.47
−3.00

68
69

.146
.004

−0.688
−1.32
0.002

1

.491
.187
.969

0.44

2

.803

1.18

1

.277

3.42

1

.064

1.51
−0.83
−0.78
−1.77
−0.65
0.29
−0.49
1.31

63
63
63
62
62
63
63
1

.138
.412
.441
.082
.519
.770
.628
.520

28.8 (7.8)
3.5 (1.5)
Range = 1–9
40.5 (31.7)
64.0 (207.8)
12 (23.1)
40 (76.9)

4 (23.5)
13 (76.5)

19 (36.5)
18 (34.6)
15 (28.9)

8 (44.4)
6 (33.3)
4 (22.2)

21 (46.7)
24 (53.3)

10 (62.5)
6 (37.5)

32 (71.1)
13 (28.9)

15 (93.8)
1 (6.2)

48.3 (20.0)
49.5 (20.0)
−0.28 (1.21)
−0.17 (0.96)
−0.13 (0.61)
−0.13 (0.42)
−0.13 (0.61)

37.1 (12.7)
55.9 (18.3)
0.01 (1.37)
0.36 (0.30)
−0.01 (0.52)
−0.17 (0.51)
−0.05 (0.51)

38 (71.7)
13 (24.5)
2 (3.8)

15 (82.3)
2 (11.8)
1 (5.9)

Test Statistics

Note: TR, treatment resistant; AP antipsychotic medications; MRI, Magnetic resonance imaging; df, degrees of freedom; DUP, Duration
of untreated psychosis; GAF, Global Assessment of Functioning Scale.
Table 2. Graph Variables and Their Effect Sizes in the TR and non-TR Groups
Graph Variables

Path length (λ)
Clustering coefficient (ϒ)
Small-worldness (σ)

FDA Mean (SD)
Non-TR(N = 53)

TR (N = 17)

0.93 (0.13)
1.86 (0.10)
2.09 (0.28)

1.21 (0.12)
1.74 (0.16)
1.51 (0.28)

F value (P-value)

Hedges’ g

60.39 (<.001)
14.66 (<.001)
56.02 (<.001)

−2.17
1.07
2.09

Note: TR, treatment resistance; FDA, Functional Data Analysis; all 3 comparisons survived Bonferroni correction for multiple testing
(ie, P < .016). Also see supplementary figure 1.

Discussion
To our knowledge, this is the first study to have examined
the value of gyrification at illness onset as a predictor of
TR occurring over the subsequent 4 years. Our results
point to an association between a reduced coordination
of processes driving cortical folding at the whole brain
level (σ), stemming from both a neighborhood-level disruption (λ) and a reduced distributed relationship (ϒ),
1734

and the onset of TR. Thus, patients with first-episode
psychosis who later developed TR, already displayed, at
first presentation, a significant aberration in cortex-wide
covariance of folding patterns when compared to patients who do not go on to develop TR. This indicates
that the development of TR is likely related to the maturational coordination of the entire cortex, rather than to
the degree of folding of any single region.

Structural Covariance of Cortical Gyrification

While structural covariance has not been examined in
relation to prospectively determined TR to date, a recent
study reported that thickness-based group-level structural covariance was not altered at whole brain level in patients with chronic schizophrenia resistant to treatment;
instead, covariance was only higher among those regions
that showed reduced thickness in TR.62 In contrast, here
we report an overall reduction in gyrification-based,
perturbation-derived patient-level structural covariance
in relation to TR. While thickness-based covariance has
been interpreted as an index of intra-cortical connectivity,62 gyrification-based covariance is best interpreted
as an index of synchronized early maturation, given the
in-utero synchronization of sulcal development.63 Thus,
the reduction of small-worldness in perturbation-based
LGI networks probably indicates a loss of coordination
in cortical folding at the whole brain level, likely occurring
during early development.
In contrast to our previous observations when contrasting short-term (12-week) responders with nonresponders,27 we did not observe localized differences in

Fig. 2. Plot depicting the relationship, adjusted for TR status,
age and sex and the positive symptom dimension, between the
residuals of small-worldness index (σ) and positive symptom
dimension in the entire sample. Also, see supplementary figure 2.

gyrification between patients who later developed TR and
those who did not. This supports the prevailing notion
that TR is unlikely to be related to specific neuroanatomical defects.64,65 Instead, it may rather relate to a diffuse
but subtle neurodevelopmental aberration that occurs
either in utero or in early life. Consequently, it is likely
that we observe no localizable effects, and that instead
disrupted maturational relationships (covariance) among
brain regions result in abnormal network-level topology.
Here, we observe reduced regional segregation (clustering) and reduced overall integration of the morphological connectome, resulting in reduced small-worldness
in covariance. Given the major role played by axonal
tension in the formation of cortical folds,66,67 we surmise
that TR results from a weakening of axonal tensions that
arise from reduced inter-regional connectivity in the neonatal brain. As a result, the folding of spatially proximal,
physically connected brain regions may not be synchronized and result in reduced clustering. Although the large
effect size changes we find indicates >90% chance68 that
a randomly selected patient with first-episode psychosis
could be correctly identified to come from the TR group
based on the reduced small-worldness of their cortical
morphology, it remains unclear how well this prediction
would perform at a single patient level.
Intriguingly, we found higher small-worldness was
correlated with higher levels of positive symptoms at
illness onset, and that small-worldness was reduced
among patients with TR. Some evidence on the neurobiology of TR suggests that patients with TR may have
a normodopaminergic/hyperglutamatergic status, while a
predominantly hyperdopaminergic/normoglutamatergic
status (ie, increased presynaptic dopamine) could relate to a higher degree of treatment responsiveness.3,69–71
Consistent with these suggestions, we speculate that a
substantial number of individuals with a predominantly
hyperdopaminergic pattern and higher positive symptoms at presentation may not have a notable cortical maturational deficit resulting in increased small-worldness
of gyrification networks. However, those with less maturational coordination of cortical folding may go on to

Table 3. Correlation Between Graph Variables and Symptom Dimensions

Positive dimension
Negative dimension
Disorganized dimension
Excited symptom dimension
Depressed symptom dimension

Small-Worldness (σ)

Path Length (λ)

Clustering Coefficient (ϒ)

r (P-value)

r (P-value)

r (P-value)

.41 (.001)a
−.14 (.30)
.20 (.12)
−.19 (.14)
−.038 (.76)

−.34 (.006)
.08 (.52)
−.18 (.18)
.16 (.21)
−.23 (.06)

.33 (.008)
−.15 (.24)
.12 (.34)
.21 (.09)
−.07 (.59)

Note: Unstandardized residuals adjusted for binary TR status, age and sex. r = Pearson correlation coefficient; degree of freedom df = 64
for each correlation.
a
Survives Bonferroni correction for multiple testing (ie, P < .005).
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exhibit TR. The case for a neurodevelopmental characterization of TR is further strengthened by the observation
that a younger age of onset,72 low IQ and family history of
schizophrenia are all associated with TR.73 Prospectively
designed hybrid PET/MR and glutamate MRS studies
would help test the notion that a neurodevelopmental
subtype with predominant glutamatergic deficits is specifically associated with TR.
It is noteworthy that network methods used in previous
cross-sectional structural covariance studies also relied
on group-based correlation,74 but the edges of those networks represented population-level (ie, between-subjects)
relationships among regional gyrification indices. In contrast, the edges derived from our approach using deviance matrices represent the estimated relationship at an
individual level (within-subject). Thus, the topological
metrics from our network approach, based on secondorder statistics (distance vs. correlation coefficient), are
likely idiographic. The edges between 2 regions (nodes) in
the individual gyrification networks do not imply direct
connectivity but represent the absolute contribution each
individual makes to the observed group-specific coordination in gyrification.
Methodological Considerations
The strengths of this study include the evaluation of brain
morphology at the time of the first presentation to services, and the prospective evaluation of illness course over
the first 4 years of illness. We have examined the onset
of TR from the time of first contact with mental health
services. The factor model of psychosis symptoms we
used was derived from previous studies56 and shown to be
optimal for the evaluation of patients with first-episode
psychosis.75–77 The symptom dimensions were based on
the PANSS, which has been shown to be resilient to the
effects of age, chronicity of illness78 and short-term medication withdrawal.79 As the MRI data were obtained at
the first-episode, before the evolution to TR status, the
findings are not likely to be confounded by chronicity of
illness or prolonged exposure to medications.
Although our length of DUP was consistent with that
of other cohorts of first-episode psychoses,80–82 it was
still shorter than that reported in some other studies.83–85
Given the variability in the definitions of DUP,86 we urge
caution when generalizing our observations to all studies
of first-episode psychosis. It is also possible that some
patients in the non-TR group could have been TR but
were unable did not accept or tolerate clozapine; similarly, it is also possible that some individuals in the
non-TR group could have developed TR if they were followed up over a longer time period of time. However, we
believe this latter possibility is unlikely, as we have previously shown that in most cases, TR becomes apparent
early in the course of illness. Although evidence suggests
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there may be an early and a late treatment-resistant subtype,4,5 we did not have a sufficient number of patients to
investigate if gyrification can discriminate between them.
Similarly, it is feasible that a relatively small and unbalanced number of patients could have had an impact on
our results. Nonetheless, our sample size is consistent
with that of previous reports,3,16,22,25 and the definition
of TR we used took into account instances when antipsychotics were stopped due to side effects rather than
lack of improvement, thus ensuring it reflected true
TR. Finally, the lack of a healthy control group limits
our ability to comment on whether the patterns seen in
non-TR individuals are “deviant” from those of individuals without a diagnosis of psychosis. As we now know
what are the demographic and socioeconomic profiles of
patients that are likely to develop TR over 4 years, we
anticipate undertaking future matched data-collection
with cohorts of healthy subjects that match the predicted
non-TR and TR groups.
Conclusion
Several putative mechanistic pathways that ultimately
result in treatment resistance in psychotic disorders may
converge on disruption of coordinated cortical maturation. Our observations raise the possibility of defining
a therapeutically meaningful “neurotype” of psychosis
based on an easily accessible structural imaging assay of
cortical folding patterns.
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